Citius Oncology Inc

CTOR

Add to Watchlist

0.963USD

-0.021-2.13%

Close 05/15, 16:00（ET）Quotes delayed by 15 min

Citius Oncology Inc's Score

Industry at a Glance

Industry Ranking

198 / 382

Overall Ranking

382 / 4482

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Citius Oncology Inc Highlights

StrengthsRisks

Citius Oncology, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing targeted oncology therapies. The Company’s lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. LYMPHIR is a targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) indicated for use in Stage I-III disease after at least one prior systemic therapy. It is a recombinant fusion protein that combines the IL-2 receptor binding domain with diphtheria toxin fragments. The agent specifically binds to IL-2 receptors on the cell surface, causing diphtheria toxin fragments that have entered cells to inhibit protein synthesis. After uptake into the cell, the diphtheria toxin (DT) fragment is cleaved and the free DT fragments inhibit protein synthesis, resulting in cell death.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Overvalued

The company’s latest PE is -0.65, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 7.13M shares, decreasing 44.77% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 0.00 shares of this stock.

Analyst Rating

Based on 1 analysts

Buy

Current Rating

6.000

Target Price

+509.57%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Citius Oncology Inc is 6.85, ranking 174 out of 382 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.85

Change

0



Financials

5.04

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.61

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

3.01

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.57

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Citius Oncology Inc is 5.76, ranking 353 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.65, which is 0.00% below the recent high of -0.65 and -391.02% above the recent low of -3.20.

Score

Industry at a Glance

Previous score

5.76

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 198/382

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Citius Oncology Inc is 6.00, ranking 333 out of 382 in the Biotechnology & Medical Research industry. The average price target is 6.00, with a high of 6.00 and a low of 6.00.

Score

Industry at a Glance

Previous score

6.00

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Citius Oncology Inc is 3.98, ranking 355 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 1.04 and the support level at 0.85, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

4.13

Change

-0.15

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-05-15

Score

Industry at a Glance

Previous score

3.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Citius Pharmaceuticals Inc

66.05M

--

Armistice Capital LLC

5.58M

-27.25%

10XYZ Holdings LP

1.98M

-3.18%

Bartushak (Jaime)

825.00K

--

Geode Capital Management, L.L.C.

220.05K

+31.63%

Independent Financial Partners

87.42K

+163.21%

OMERS Administration Corporation

104.50K

--

XTX Markets LLC

73.99K

-41.69%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. No risk assessment score is currently available for Citius Oncology Inc. The Biotechnology & Medical Research industry's average is 3.36. The company's beta value is 3.58. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.

Citius Oncology Inc

CTOR

4.87 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Krystal Biotech Inc

KRYS

8.57 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.57 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.48 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Exelixis Inc

EXEL

8.44 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.44 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment